Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
clinical trial
Advertisement
Shionogi Launches ZURZUVAE for Major Depression in Japan
OSAKA, Japan, March 19, 2026 Shionogi & Co., Ltd. has officially announced the commercial launch of ZURZUVAE® (zuranolone) 30...
FDA Grants IDE Approval for OCS Heart ENHANCE Trial
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
ReDS-Guided Strategy Reduces 30-Day Heart Failure Readmissions
MADRID & NEW YORK, January 29, 2026 — A multicenter randomized clinical trial has demonstrated that remote dielectric sensing...
Opus Initiates Gene Therapy Trial for MERTK Retinal Disease
Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...
Advertisements
PulseSight Completes Phase I Dosing of PST-611 in Dry AMD
Paris, France | January 22, 2026 — PulseSight Therapeutics, a Paris-based clinical-stage biotechnology company, has announced the successful completion...
Columvi Combo Doubles Survival in Three-Year STARGLO Results
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
Rondo Therapeutics Begins Phase I Trial of RNDO-564 in Advanced Tumors
Dateline – San Francisco, CA – December 2025: Rondo Therapeutics has dosed the first patient in its Phase I...
Feinstein Institutes Wins $3.37M Grant to Boost First-Responder Mental Health
MANHASSET, N.Y. — November 27, 2025: Feinstein Institutes for Medical Research, in collaboration with Stony Brook University and Texas...
Enlivex Reports Strong 6-Month Data for Allocetra in Knee Osteoarthritis
Nes-Ziona, Israel — Nov. 24, 2025 — Enlivex Therapeutics Ltd. announced positive six-month topline results from the Phase IIa...
Advertisement
